DEPOMED INC Form 8-K March 14, 2016

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# Form 8-K

## **Current Report**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2016

# **DEPOMED, INC.**

(Exact name of registrant as specified in its charter)

#### 001-13111

(Commission File Number)

California
(State or other jurisdiction of incorporation)

94-3229046 (I.R.S. Employer Identification No.)

7999 Gateway Blvd, Suite 300, Newark, California 94560


(Address of principal executive offices, with zip code)

(510) 744-8000

(Registrant s telephone number, including area code)

### Not Applicable

(Former name or former address, if changed since last report)



- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 7.01 Regulation FD Disclosure**

On March 14, 2016, Depomed, Inc. ( Depomed ) presented an investor presentation at the Annual ROTH Conference. A copy of the investor presentation is attached hereto as Exhibit 99.1.

This information is being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed to be filed for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Depomed, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is being disclosed pursuant to Regulation FD.

### **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No. Description

99.1 Depomed, Inc. Presentation Materials dated March 14, 2016

2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## DEPOMED, INC.

Dated: March 14, 2016 /s/ Matthew M. Gosling

Matthew M. Gosling

Senior Vice President and General Counsel

3